Neurocrine Biosciences (NBIX) Releases Earnings Results, Beats Expectations By $0.03 EPS

Neurocrine Biosciences (NBIX) reported quarterly earnings results on Wednesday, Aug-3-2016. The company said it had a profit of $-0.46 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.03. Analysts had a consensus of $-0.49. During the same quarter in the previous year, the company posted $-0.28 EPS.

Many Wall Street Analysts have commented on Neurocrine Biosciences. H.C. Wainwright Initiated Neurocrine Biosciences on Jun 29, 2016 to “Buy”, Price Target of the shares are set at $80.

Neurocrine Biosciences closed down -1.08 points or -2.10% at $50.43 with 6,92,194 shares getting traded on Tusday. Post opening the session at $51.27, the shares hit an intraday low of $49.57 and an intraday high of $51.3275 and the price fluctuated in this range throughout the day.Shares ended Tusday session in Red.

In a different news, on Jun 2, 2016, Malcolm Lloyd-smith (Chief Regulatory Officer) sold 9,000 shares at $50.00 per share price. According to the SEC, on Jun 2, 2016, Christopher Flint Obrien (Chief Medical Officer) sold 12,500 shares at $50.00 per share price. On May 26, 2016, Richard F Pops (director) sold 15,000 shares at $46.72 per share price, according to the Form-4 filing with the securities and exchange commission.

Neurocrine Biosciences Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine based diseases and disorders. The Company’s two lead late-stage clinical programs are elagolix a gonadotropin releasing hormone (GnRH) antagonist for women’s health that is partnered with AbbVie Inc. (AbbVie) and a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. elagolix is in clinical trials for the treatment of Endometriosis and Uterine Fibroids. VMAT2 (NBI-98854) is a VMAT2 inhibitor in clinical trials for the treatment of tardive dyskinesia. Corticotropin-Releasing Factor (CRF) receptor antagonist (NBI-77860) is indicated for the treatment of Classic Congenital Adrenal Hyperplasia. NBI-77860 is a selective orally-active non-peptide CRF receptor antagonist.

Neurocrine Biosciences

Leave a Reply

Neurocrine Biosciences - Is it time to Sell?

Top Brokerage Firms are advising their investors on Neurocrine Biosciences. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.